On February 12, 2019, Johnson & Johnson announced the acquisition of Auris Health, a medical robotics company founded by one of the pioneers of robotic surgery. The deal was valued at up to $5.75 billion: $3.4 billion in cash at closing, plus an additional $2.35 billion in “milestone payments” if J&J successfully steered Auris’s surgical robots through FDA regulatory approval and hit certain sales targets over the next few years.

It was framed as a marriage of innovation and scale. Auris had the cutting-edge technology. J&J had the resources, the regulatory expertise, and the global distribution network. The milestone structure was designed to align incentives and reward success. On paper, everyone won.

In practice, Johnson & Johnson systematically sabotaged every single milestone, pocketed the contingent payments, and walked away. And they almost got away with it.

On January 12, 2026, the Delaware Supreme Court handed down an 89-page opinion affirming that J&J committed both breach of contract and fraud in connection with the Auris acquisition. The court upheld over $1 billion in damages. This is the story of what J&J did, how they justified it internally, and what the legal system finally forced them to pay for it.

The Facts: The Deal That Was Too Good to Be True

Auris Health was not a typical acquisition target. The company was founded in 2012 by Dr. Frederic Moll, a robotic surgery legend and one of the co-founders of Intuitive Surgical, the company behind the da Vinci surgical robot that dominates operating rooms worldwide. Dr. Moll started Auris to push robotic technology beyond the da Vinci platform into new, minimally invasive procedures, particularly in endoscopy.

By 2019, Auris had two flagship robotic platforms in development. The first was Monarch, a robotic endoscopy system designed for diagnosing and treating lung cancer. The second was iPlatform, a versatile robotic surgical system designed to compete directly with da Vinci and extend beyond it. iPlatform was bed-mounted rather than cart-based, giving it a smaller footprint in the operating room. It featured six robotic arms (two more than da Vinci’s four), a surgeon’s console, and a central control tower. Auris had successfully demonstrated iPlatform in lab settings, including key procedures on cadavers, and by the end of 2018, iPlatform had reached “concept freeze,” meaning the core design was locked and ready for regulatory review.

J&J had been tracking Auris for years. As robotic surgery expanded in the 2010s, J&J came to view surgical robots as critical to protecting its lucrative instrument business. Hospitals using da Vinci purchased Intuitive-branded instruments rather than traditional tools from J&J’s Ethicon subsidiary. Internal J&J documents characterized Intuitive’s growth as an “existential threat.” J&J set out to develop its own robotic platform, called Verb, through a joint venture with Verily Life Sciences (an Alphabet subsidiary). But Verb fell behind schedule and encountered technical challenges. By late 2018, J&J began looking externally for robotics expertise and identified Auris as a key acquisition target.

Negotiations moved quickly. Because so much of Auris’s value lay in future regulatory and commercial success, J&J proposed bridging the valuation gap with contingent consideration. The deal paired a large upfront cash payment ($3.4 billion) with substantial earnouts ($2.35 billion) tied to post-closing milestones. Auris was willing to accept that structure only if J&J committed to driving the Auris platforms hard after closing. J&J assured Auris that it would bring J&J-scale resources, allow Auris to continue operating with a “light touch” integration model, and treat Auris’s robots as priority programs.

The final Merger Agreement included ten milestones: eight tied to specific FDA regulatory approvals (five for iPlatform, two for Monarch, and one that either platform could satisfy) and two tied to aggregate sales performance. Every single regulatory milestone was explicitly conditioned on obtaining “510(k) premarket notification,” a specific type of FDA clearance for medical devices. The 510(k) pathway is historically the fastest and least burdensome route to approval for moderate-risk devices, requiring the manufacturer to show that the new device is “substantially equivalent” to an already-cleared predicate device.

The Merger Agreement required J&J to use “commercially reasonable efforts” to achieve each regulatory milestone. That term was carefully negotiated and specifically defined. It meant J&J had to devote efforts and resources “consistent with the usual practice of [J&J] and its Affiliates with respect to priority medical device products of similar commercial potential at a similar stage in product lifecycle.” In simpler terms, J&J had to treat Auris’s robots the same way it treated its own priority projects. The contract listed ten factors J&J could consider in calibrating its efforts, including safety, development risk, regulatory difficulty, and expected profitability. But the baseline was clear: priority device treatment.

The Merger Agreement also included an anti-sabotage clause. Section 2.07(e)(iii) prohibited J&J from taking “any action” either “with the intention of avoiding any of [J&J’s] obligations to pay any Earnout Payment” or “based on taking into account the cost of making any Earnout Payment.”

On April 1, 2019, the acquisition closed. Auris’s stockholders received $3.4 billion in cash. Fortis Advisors LLC became the designated representative of the former Auris stockholders for purposes of administering the earnout. From that point forward, the development and regulatory progress of Monarch and iPlatform would determine whether Auris’s stockholders received any additional consideration.

They would receive nothing.

The Misconduct: Project Manhattan and the Systematic Destruction of iPlatform

The Bakeoff

Within days of closing, J&J launched an initiative code-named “Project Manhattan.” Officially, it was described as a technical assessment of Auris’s iPlatform and J&J’s Verb. In practice, it was a winner-take-all internal competition between the two systems. An internal J&J document described Project Manhattan as a plan to “assess the robotic system development status from Verb and Auris and recommend an optimal path to bring the system(s) to market,” outlining three possible outcomes: develop both platforms in parallel, choose one, or merge them into a single system.

The competition format pulled iPlatform squarely off its regulatory milestone track. Over an intensive 25-day period, eight leading surgeons were asked to perform seven demanding procedures on both iPlatform and Verb. Those procedures included a Roux-en-Y gastric bypass, a low anterior resection, and a lobectomy. These were substantially more complex than the initial indications Auris had planned to use to satisfy the first milestone. To prepare, more than 80 Auris personnel were diverted from the development roadmap to ready a months-old alpha prototype for a rapid face-off against a more mature, post-beta Verb system. Auris engineers spent weeks patching bugs and stabilizing the system with ad hoc software and hardware fixes. The Delaware Court of Chancery described this work as “the engineering and software equivalent of Band-Aids, duct tape, and baling wire,” incurring “significant ‘technical debt'” and driving the program “backwards rather than forwards in development.”

Although iPlatform ultimately “won” Project Manhattan (both robots completed all seven procedures, and J&J concluded that iPlatform was the better platform), the Delaware Supreme Court held that “Project Manhattan alone is sufficient to find that J&J breached its efforts obligation.” The exercise did not advance iPlatform’s regulatory milestones, provide additional resources, or move the device closer to clearance. It “caused needless setbacks and resource drains” for iPlatform while generating synergies that primarily benefited Verb and J&J’s budget constraints. As the court put it, a priority device “would not have to endure a costly battle merely to remain operative.”

The Forced Integration

After Project Manhattan, J&J made a second critical decision. In December 2019, J&J management formally recommended to the board that it proceed with “a combined platform where Auris’s iPlatform is augmented by Verb assets including the open surgeon console, intra-procedure data capabilities and the surgeon portal,” branding the resulting system “iPlatform+.”

Although the Merger Agreement permitted J&J to achieve the milestones using a combined device, the manner in which J&J executed that combination breached its commercially reasonable efforts obligations. J&J initiated a “full speed migration” of more than 200 Verb employees onto the iPlatform team. Auris leadership was largely sidelined. Hostility festered between the two groups, which had just battled against each other in Project Manhattan. Within a year, every engineer from the legacy iPlatform clinical engineering team had left. Verb software engineers insisted on rewriting iPlatform’s code, prompting significant attrition among Auris’s software developers as well. The combination effectively left iPlatform as “a parts shop for Verb.”

The Delaware Court of Chancery held that the Verb combination and integration directly violated J&J’s contractual obligations. Approving the combination based in part on “what would also happen with the contingent payment” was not only inconsistent with J&J’s duty to use commercially reasonable efforts to achieve the milestones, but was also contrary to Section 2.07(e)(iii)’s express prohibition on making decisions “based on taking into account the cost of making any Earnout Payment.”

The MVP Abandonment

The regulatory milestones were structured consistently with a “minimally viable product” (MVP) strategy, a standard approach in the medical device industry. Under an MVP strategy, a company first seeks regulatory clearance for a simplified device configuration performing narrower, lower-risk indications. Once that stripped-down device is cleared, it can serve as its own predicate for future 510(k) submissions, allowing the manufacturer to add features and indications over time.

For Milestone 1 (the $400 million “General Surgery Milestone”), the Merger Agreement required iPlatform to obtain 510(k) clearance for “one upper abdominal surgical procedure and one lower abdominal procedure” by the end of 2021. Auris had concluded that targeting complex procedures like Roux-en-Y gastric bypass was “out of reach for 2021” and had negotiated to simplify the milestones to achieve regulatory approval more quickly. The plan was to focus on basic laparoscopic procedures (such as single-quadrant gallbladder or hernia repairs) that the prototype was “very capable” of performing.

After the acquisition, J&J abandoned the MVP strategy and instead insisted on pursuing RYGB to create a full-featured, commercially attractive system that was better able to compete head-to-head with da Vinci and promote high-margin Ethicon instrument sales. Internal J&J communications reveal that management was uneasy with Auris’s single-minded focus on hitting the earnout milestone “for the sake of [the] timeline.” One J&J executive cautioned that the Auris team was too fixated on speedy clearance “as opposed to a great product with commercial viability.”

The Delaware Court of Chancery held that this pivot away from MVP toward an RYGB-first specification violated J&J’s efforts obligations. The court credited Auris’s showing that an MVP strategy better aligned with the ten factors listed in the efforts clause and noted that J&J followed an MVP approach for other priority RASD devices like Velys (J&J’s orthopedic surgical robot). J&J’s insistence that iPlatform pursue a RYGB specification “impeded the achievement of the 2021 milestone,” and the court emphasized that J&J was “not permitted to prioritize commercialization, product differentiation, or short-term profitability at the expense of achieving the milestones.”

The Write-Down

On April 14, 2020, during its quarterly earnings call, J&J disclosed that the company had written down to zero the value of all the Auris milestones. The write-down produced an immediate financial benefit for J&J: by releasing the reserves associated with the earnout, J&J recorded a gain of approximately $983.6 million in the first quarter of 2020.

Two months after the write-down, J&J implemented a revised employee incentive program that no longer rewarded Auris personnel for achieving the regulatory milestones defined in the Merger Agreement. The new plan offered a single bonus tied to the FDA clearing iPlatform for a “general surgery” indication by the end of 2023 (later than the 2021 deadline for Milestone 1 and keyed to a broader, vaguer approval rather than the two specific procedures that Milestone 1 required). Incentive awards tied to the remaining umbrella milestones were eliminated entirely. J&J executives told Auris employees that the original earnout milestones had been “canceled.”

By the end of 2021, J&J pulled the plug on iPlatform. J&J’s leadership concluded that iPlatform would not be viable within a commercially reasonable timeframe. J&J refocused its efforts on Velys and effectively shelved the iPlatform program.

None of the $2.35 billion in earnouts was ever paid.

The Fraud: The Patient Death J&J Concealed to Close the Deal

In addition to the breach of contract claims, the Delaware courts found that J&J committed fraud in the inducement of the merger in connection with one specific $100 million milestone tied to Auris’s Monarch platform. That milestone (the “Soft Tissue Ablation Milestone”) required Monarch to obtain 510(k) clearance for lung tissue ablation by the end of 2022. To achieve the milestone, Monarch would need to use J&J’s NeuWave FLEX catheter, which delivers microwave energy to ablate or destroy tissue. Although NeuWave FLEX had regulatory approval for soft tissue ablation, it was not yet approved for lung-specific use.

On January 24, 2019, during merger negotiations, J&J’s CEO Alex Gorsky pitched the milestone to Auris, explaining that there was such a “high certainty” of achieving the milestone that J&J viewed it as an “effective up front payment.” In reality, the milestone “was not remotely certain to be met.”

Here is what Gorsky knew and did not disclose. In June 2018, J&J had initiated a ten-patient study using FLEX to treat lung lesions. On December 4, 2018, a study participant died weeks after being treated with FLEX. On December 13, 2018, the FDA launched a for-cause, on-site inspection into whether the study had violated FDA rules. Although J&J would not learn the outcome of the investigation until April 3, 2019, it was clear that the investigation risked substantial delay. On January 14, 2019 (ten days before Gorsky’s “high certainty” pitch), J&J’s deal team was briefed on the developments. Auris did not learn of the patient death or the FDA investigation until after the merger closed.

The Delaware Court of Chancery found all five elements of fraud. Gorsky’s statement was a false representation. J&J knew the representation was false (or, at a minimum, made it with reckless indifference to the truth). J&J intended to induce Auris to accept the milestone payment in lieu of an upfront payment. Auris relied on that statement in agreeing to the earnout. Auris was damaged when the milestone later proved unattainable within the contracted timeline.

The court awarded benefit-of-the-bargain damages for the fraud claim: $60,865,748, representing Auris’s reasonable expectation of the Soft Tissue Ablation Milestone’s value at the time of J&J’s fraud.

The Verdict: Delaware Courts Award Over $1 Billion

On October 12, 2020, Fortis Advisors LLC, representing the former Auris stockholders, filed suit in the Delaware Court of Chancery against J&J. After extensive discovery, the case went to trial in January 2024. The trial lasted ten days, with 23 fact witnesses and nine expert witnesses, supported by more than 6,200 joint exhibits.

On September 4, 2024, the Court of Chancery issued a 144-page opinion ruling in Fortis’s favor on the most significant issues. The court held that J&J breached the Merger Agreement by failing to use the required commercially reasonable efforts to achieve the iPlatform regulatory milestones and by acting to avoid the earnouts. The court also found that J&J, through its CEO, fraudulently induced Auris to accept the $100 million Soft Tissue Ablation Milestone instead of immediate fixed consideration.

The court awarded a total judgment amount of $1,011,271,291, inclusive of $900,000,000 in contract damages, $60,865,748 in fraud damages, and $42,405,543 in pre-judgment interest.

J&J appealed. On January 12, 2026, the Delaware Supreme Court issued its decision. The Supreme Court reversed the trial court on one narrow legal issue related to the implied covenant of good faith and fair dealing. After the merger closed, the FDA changed its regulatory policy and closed the 510(k) pathway for first-generation robotic surgical devices like iPlatform, requiring them to go through a more rigorous “De Novo” review process instead. The trial court had used the implied covenant to hold that J&J was required to pursue De Novo approval and treat it as the functional equivalent of the 510(k) approval specified in the contract.

The Supreme Court reversed that holding, finding that the risk of an FDA pathway change was foreseeable and addressed in the parties’ agreement. The Merger Agreement explicitly tied the regulatory milestones to 510(k) clearance and contained provisions acknowledging that FDA “developments” could affect the route, timing, or cost of approval. The Supreme Court held that there was no contractual gap for the implied covenant to fill. Accordingly, the Supreme Court vacated the damages awarded for Milestone 1 (the $400 million General Surgery Milestone).

However, the Supreme Court affirmed the trial court on every other issue. The Supreme Court adopted the trial court’s interpretation of the “commercially reasonable efforts” clause and upheld the finding that J&J breached its express obligation to use commercially reasonable, “priority” device efforts to achieve the remaining iPlatform regulatory milestones. The Supreme Court also affirmed the trial court’s fraud finding and held that the Merger Agreement’s exclusive remedy clause did not bar Fortis’s fraud claim in the absence of an express anti-reliance provision from Auris.

The Supreme Court remanded the case to the trial court to recalculate the judgment consistent with its opinion. Even after excluding the Milestone 1 award, the remaining contract damages ($500 million for the four umbrella milestones plus $150 million for the GI milestone) plus fraud damages ($60.8 million) plus pre-judgment interest will exceed $600 million.

The Non-Financial Ledger: What the Dollar Figures Don’t Capture

Dr. Frederic Moll spent seven years building Auris. He recruited senior engineering talent from across the robotics field. He built functional prototypes that successfully demonstrated life-saving procedures. By the end of 2018, iPlatform had reached concept freeze and was ready for regulatory review. Moll and his team believed they were building the next generation of surgical robotics. They believed they were going to save lives.

Then J&J bought the company. Within 25 days, J&J forced the Auris team into a head-to-head competition against J&J’s own failing robot. Within a year, J&J flooded the team with 200 Verb employees, sidelined Auris leadership, and triggered mass attrition. By the end of 2021, every engineer from the legacy iPlatform clinical engineering team had left. iPlatform was shelved. Moll’s life’s work was reduced to a “parts shop” for Verb.

Auris employees were told their milestones had been “canceled.” Their incentive bonuses were replaced with vaguer targets tied to timelines that J&J knew were unachievable. They watched as J&J executives explicitly calculated that the “overall value case” improved when you considered “what will also happen with the contingent payment”—meaning, when the milestones fail.

Engineers who dedicated years to a mission-driven startup watched their work deliberately sabotaged for short-term accounting gains. The $983.6 million write-down that J&J booked in Q1 2020 was not an admission of failure. It was a declaration of victory. J&J had successfully avoided paying $2.35 billion in earnouts by making sure no earnouts would ever be earned.

The legal term for this is breach of contract. The human term is betrayal.

Legal Receipts: What J&J’s Own Documents Say

The Delaware courts did not base their findings on speculation or inference. The findings were based on J&J’s own internal documents and emails. Here is what J&J wrote when they thought no one was watching:

These are not allegations. These are J&J’s own words, entered into evidence, authenticated, and cited in a published court opinion.

Societal Impact Mapping: What This Means for Innovation, Healthcare, and Corporate Power

Economic Inequality: The Earnout as a Weapon

Earnout structures are common in startup acquisitions. In theory, earnouts align incentives: the buyer gets to reduce upfront risk, and the seller gets rewarded if the business succeeds post-acquisition. In practice, earnouts hand the buyer a loaded gun. The acquirer controls the resources, the strategy, and the timeline. If the acquirer wants to avoid paying the earnout, it can simply starve the acquired business of support, divert talent to competing internal projects, or change strategic priorities.

That is exactly what J&J did. The Merger Agreement attempted to guard against this by requiring J&J to use “commercially reasonable efforts” and by prohibiting J&J from acting “with the intention of avoiding” the earnouts. But as this case demonstrates, those protections are only as strong as the plaintiff’s ability to litigate for five years and survive summary judgment. Most startups cannot afford that fight. Most earnouts are simply stolen, and no one ever knows.

The Delaware Supreme Court’s decision sets a critical precedent. It establishes that a buyer cannot invoke vague business justifications to sabotage earnouts. It establishes that “commercially reasonable efforts” must be measured against the buyer’s own treatment of its priority projects. And it establishes that buyers cannot hide behind exclusive remedy clauses to immunize themselves from fraud liability for lies told during negotiations.

But precedent only matters if plaintiffs can enforce it. The Auris stockholders had the resources to fight. Most don’t.

Public Health: The Medical Devices That Will Never Reach Patients

iPlatform was not vaporware. It was a functional surgical robot that successfully demonstrated complex procedures on cadavers. It had reached concept freeze and was ready for FDA review. Auris’s engineers believed iPlatform could have been cleared for its first indication by the end of 2021 if J&J had simply let them work.

Instead, J&J killed it. Not because iPlatform didn’t work. Not because it was unsafe. Not because there was no market for it. J&J killed it because paying $2.35 billion in earnouts was more expensive than absorbing iPlatform into Verb and writing off the milestones as unachievable.

How many surgical patients could have benefited from a da Vinci competitor with a smaller operating-room footprint and six robotic arms instead of four? How many hospitals would have chosen iPlatform if it had reached the market in 2021? We will never know, because J&J made sure it never reached the market.

This is not unique to J&J. The medical device industry is littered with acquisitions where the buyer purchases a promising technology, shelves it to eliminate a competitive threat, and moves on. The only thing unusual about this case is that J&J got caught.

Environmental Degradation: The Externalities We Don’t Count

This case is not an environmental case. But it is part of a broader pattern. Johnson & Johnson is a company with a long history of environmental and public health misconduct. J&J’s talc-based baby powder was linked to ovarian cancer and mesothelioma, resulting in tens of thousands of lawsuits and a $9 billion settlement. J&J’s subsidiary Janssen Pharmaceuticals marketed opioid painkillers in ways that contributed to the opioid epidemic. J&J has been repeatedly fined for Clean Water Act violations at its manufacturing facilities.

When a company engages in this level of misconduct across multiple domains—fraud, environmental harm, public health—what we are seeing is not a series of isolated incidents. We are seeing a business model. The business model is: maximize profit, externalize harm, and litigate when caught.

The Auris acquisition fits this pattern. J&J made a calculated decision to breach the Merger Agreement, defraud Auris, and absorb the litigation risk. Even with the $1 billion judgment, J&J saved money. They paid $3.4 billion upfront instead of $5.75 billion total. They booked a $983 million gain in Q1 2020 by writing off the earnouts. They eliminated a competitive threat to Verb. From a pure profit-maximization standpoint, this was a successful strategy.

The question we have to ask is: why is this legal? Why is a corporation allowed to negotiate a contract in bad faith, breach it deliberately, and simply pay damages if they get caught? The answer is that our legal system treats contract breach as a cost of doing business rather than as a form of theft. Corporations price in the risk of getting sued. If the expected payout is less than the profit from the breach, the breach is rational.

Until the damages exceed the profit, nothing changes.

What Now? The Watchlist and What You Can Do

Johnson & Johnson is a publicly traded company (NYSE: JNJ). Its CEO is Joaquin Duato. Its Executive Vice President and Chief Financial Officer is Joseph Wolk. Its Board Chair is Anne M. Mulcahy. These individuals lead a corporation that the Delaware courts have now confirmed committed both contractual breach and fraud. They are accountable.

The following regulatory bodies have jurisdiction over various aspects of J&J’s conduct described in this case:

• U.S. Food and Drug Administration (FDA): Regulates medical device approvals, clinical trials, and device safety reporting.
• U.S. Securities and Exchange Commission (SEC): Regulates financial disclosures by publicly traded companies, including the accounting treatment of earnouts and contingent liabilities.
• U.S. Federal Trade Commission (FTC): Investigates anti-competitive mergers and acquisitions under antitrust law.
• U.S. Department of Justice (DOJ), Antitrust Division: Prosecutes criminal and civil antitrust violations, including monopolization and anti-competitive acquisitions.

If you are an engineer, scientist, or startup founder: document everything. Every email, every meeting note, every internal presentation. The only reason the Delaware courts had evidence of what J&J did is because Auris’s legal team subpoenaed internal communications. If you are acquired and the buyer starts sabotaging your milestones, you need evidence.

If you are a stockholder: ask why your company is paying $1 billion in avoidable legal judgments. Ask why executive leadership prioritized short-term accounting gains over long-term innovation. Ask why your board of directors allowed this to happen.

If you are a healthcare worker: ask why promising medical technologies disappear after acquisition. Ask why da Vinci has no meaningful competitors. Ask why hospital procurement decisions are shaped by corporate consolidation rather than patient outcomes.

If you are a lawmaker: ask why contract law is so weak that corporations can breach with impunity. Ask why fraud damages are capped at benefit-of-the-bargain when the harm is structural. Ask why antitrust enforcement has been so thoroughly dismantled that a company like J&J can acquire competitors and kill them without consequence.

The resistance to this system is not petitions or hashtags. It is lawsuits, investigations, and enforcement. It is refusing to let corporations price in the cost of betrayal. It is demanding that harm be accounted for in the actual ledger, not just the Non-Financial one.

Support organizations fighting corporate power. Fund litigation nonprofits. Vote for lawmakers who support antitrust enforcement and who will empower regulatory agencies to actually regulate. If you are in a position to whistleblow, do it. If you are in a position to organize, do it. If you are in a position to sue, do it.

This system does not change because corporations have a moral awakening. It changes because we make it more expensive to cheat than to comply.